Last reviewed · How we verify
NCT00793247
A Double-Blind, Placebo-Controlled, Cross-Over, Multiple (n=1) Trial to Evaluate the Effects of R093877 in Patients With Chronic Intestinal Pseudo-Obstruction (CIP).
Phase 2 trial testing PRU-PLA-PRU-PLA in Chronic Intestinal Pseudo-Obstruction. Completed.
Quick facts
| Lead sponsor | Movetis |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- PRU-PLA-PRU-PLA — full drug profile →
- PLA-PRU-PLA-PRU — full drug profile →
- PLA-PRU-PRU-PLA — full drug profile →
- PRU-PLA-PLA-PRU — full drug profile →
Conditions studied
- Chronic Intestinal Pseudo-Obstruction — all drugs for Chronic Intestinal Pseudo-Obstruction →
Sponsor
Movetis — full company profile →
Who can join
18 and older, any sex, with Chronic Intestinal Pseudo-Obstruction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study was designed to investigate the clinical safety, tolerability and efficacy of prucalopride in improving the symptoms associated with chronic intestinal pseudo-obstruction (CIP) in subjects with CIP. The study hypothesis was that prucalopride at doses up to 4 mg is safe, well tolerated, efficacious and improves the symptoms associated with CIP.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00793247
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00793247 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Movetis
- Last refreshed: 18 November 2008
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00793247.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing